Gökden Yasemin, Özülker Filiz, Özülker Tamer
University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Internal Medicine, İstanbul, Turkey.
University of Health Sciences Turkey, Prof. Dr. Cemil Taşcıoğlu City Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey.
Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):96-103. doi: 10.4274/mirt.galenos.2022.38247.
The present study aimed to identify the prevalence of focal uptake in the colon on fluorine-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) studies performed for the evaluation of malignancies other than colon, to detect the rate of malignancy in incidental focal F-FDG avid colonic lesions and to investigate if any possible role of maximum standardized uptake value (SUV) values in the discrimination of malignant lesions from premalignant and benign ones exist.
We retrospectively reviewed the files of 8,017 patients with known or suspected malignancy, who underwent whole-body F-FDG PET/CT at our institution during the period November 2017 to November 2019. Patients showing a single site of focally increased colonic F-FDG uptake that was more intense compared to liver uptake on F-FDG PET studies and referred to colonoscopy were enrolled in the study.
Fifty two patients (83.8%) had at least 1 corresponding lesion on colonoscopy, whereas in 10 patients no lesion was detected. Subsequent histopathological examinations revealed no corresponding lesion in 13 (13.7%), a benign lesion in 18 (18.9%), hyperplastic polyp in 10 (10.5%), low-grade polyp in 16 (16.8%), high-grade polyp in 29 (30.5%) and malignant lesion in 9 (9.5%) of the focal F-FDG uptake sites. According to histopathology results, statistically no significant difference was found between the SUV measurements of malignant and benign cases (p>0.05) but the average SUV measurements of malignant cases were found to be significantly higher than lower + high-grade cases (p<0.05) and hyperplastic polyp cases (p<0.01).
In conclusion, any unexpected focal F-FDG uptake in F-FDG PET/CT studies is suspicious for malignancy and should be clarified by colonoscopy. The intensity of F-FDG uptake does not preclude the application of colonoscopy and histopathological verification of the lesion if there is any.
本研究旨在确定在为评估结肠以外的恶性肿瘤而进行的氟代脱氧葡萄糖(F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)检查中,结肠局灶性摄取的患病率,检测偶然发现的局灶性F-FDG摄取阳性的结肠病变中的恶性肿瘤发生率,并研究最大标准化摄取值(SUV)在鉴别恶性病变与癌前病变和良性病变方面是否具有任何可能的作用。
我们回顾性分析了2017年11月至2019年11月期间在本机构接受全身F-FDG PET/CT检查的8017例已知或疑似恶性肿瘤患者的病历。在F-FDG PET检查中显示结肠F-FDG摄取局灶性增加且比肝脏摄取更强烈的单个部位,并转诊至结肠镜检查的患者被纳入研究。
52例患者(83.8%)在结肠镜检查中至少有1个相应病变,而10例患者未检测到病变。随后的组织病理学检查显示,在局灶性F-FDG摄取部位中,13例(13.7%)没有相应病变,18例(18.9%)为良性病变,10例(10.5%)为增生性息肉,16例(16.8%)为低级别息肉,29例(30.5%)为高级别息肉,9例(9.5%)为恶性病变。根据组织病理学结果,恶性和良性病例的SUV测量值在统计学上无显著差异(p>0.05),但发现恶性病例的平均SUV测量值显著高于低级别+高级别病例(p<0.05)和增生性息肉病例(p<0.01)。
总之,在F-FDG PET/CT检查中任何意外的局灶性F-FDG摄取都应怀疑为恶性肿瘤,应通过结肠镜检查予以明确。如果存在F-FDG摄取,其强度并不排除进行结肠镜检查和对病变进行组织病理学验证。